How Hepatitis Outcomes Are Being Improved Via Modern Communication Methods - BDI 2/25 Future of Healthcare Communications Summit

  • 140 views
Uploaded on

Presentation: How Hepatitis Outcomes Are Being Improved Via Modern Communication Methods …

Presentation: How Hepatitis Outcomes Are Being Improved Via Modern Communication Methods
Presented by: Lance Hill, Chief Executive Officer, Within3
In 2013, a unique partnership of industry, medical associations, and healthcare professionals came together to launch a powerful professional social site focused on improving patient care in Hepatitis. Learn why it was done, what was done, and how new communication methods made it all possible.

More in: Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
140
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. The leader in healthcare professional digital collaboration solutions Within3 Solutions – Hep C Community Case
  • 2. Our potential clients often ask: How can I … • Do more with less? • Realize cost savings? • Be more responsive to the market? • Develop a more effective strategy? • Build stronger physician relationships? • Gain more timely information? How can I engage HCPs differently? 2
  • 3. Within3 provides digital collaboration solutions to help clients achieve better outcomes 3 • A platform for interactive dialogue, whether member-to-member or member-to-organization • A new business channel to facilitate deeper discussion and streamline workflow • An answer to the barriers of geography and time
  • 4. Within3 is the market leader in compliant, digital collaboration 4 8 10 15 0 2 4 6 8 10 12 14 16 # of Top 20 Pharmaceutical Clients 2011 2012 2013 About Us: • High growth collaboration company • Over 100 implementations worldwide • Users in over 140 countries • Utilized by 15 of the Top 20 pharmaceuticals • Top medical associations, agencies, non- profits, and mid-size life sciences
  • 5. Clients use Within3 solutions across the drug lifecycle 5 Clinical Pre-Launch / Market Shaping Launch / Commercial End of Patent Advisory Board / Steering Committee / Focus Group Clinical Trial Speakers Bureau Custom HCP/KOL Engagement Solutions Third Party Sponsorship
  • 6. Insights Suite & Collaboration Solutions 6 Primary Focus on: Organizational Enablement Building Deeper HCP Relationships “Collaboration Suite” Custom HCP/KOL Engagement Solutions Association / 3rd-Party Sponsorships Primary Focus on: Operational Efficiency Better Market Insight “Insight Suite” Steering Committees Clinical Trials Speakers Bureau Advisory Boards / Focus Groups
  • 7. Example – Hepatitis Circle Online HCP Community 7 Clinical Pre-Launch / Market Shaping Launch / Commercial End of Patent Advisory Board / Steering Committee / Focus Group Clinical Trial Speakers Bureau Custom HCP/KOL Engagement Solutions Third Party Sponsorship
  • 8. Case Study – Hepatitis Circle 8 In partnership with the American College of Gastroenterology and industry sponsors created a highly active, online community called Hepatitis Circle. The Solution – An Online Hepatitis Community The Challenge – Need to Educate Physicians Manufacturers need to enable non-traditional prescribers (in this case gastroenterologists) to learn more about these diseases, and to actively care for HV positive patients. The Situation – A Population Health Crisis Although several manufacturers are introducing effective oral treatments for Hepatitis into the marketing place, there is an increasing shortage of front-line healthcare professionals available to treat Hepatitis patients.
  • 9. Case Study – Hepatitis Circle Key Facts: • Launched October 2013 • Active & growing population of hepatologists and gastro- enterologists • Exceeding expectations of three pharmaceutical sponsors 9
  • 10. Case Study – Hepatitis Circle 10 Discussion topics include: • HCV Clinical Challenges • Latest Research • Patient Evaluation • Practice Management • Referrals • Treatment Insights • Recent News Twelve industry experts act as “Community Leaders” MDs access the community whenever and however is convenient for them.
  • 11. 1 2 3 4 5 Thoughtful Planning & Design Mobilizing Active Leaders Facilitating Discussion Frequent, Engaging Content Fostering Member Communication & Growth Integration with other Channels & Events Running an Effective Program How Hepatitis Circle is executed: 11 The American College of Gastroenterology provides: • Membership & Recruiting • Content Introduction • Expert Moderation • Quarterly Sponsor Updates Within3 provides: • Technology • Member Engagement Evaluation and Consulting • Ongoing Support • Quarterly Health Reporting
  • 12. Why Within3? 1. Experienced. Over 100 global implementations. 2. Turnkey. Robust services and technology to support manufacturers and agencies. 3. Compliant. Comprehensive technology and process expertise to ensure compliance. 4. Results. Our clients routinely achieve strong improvements to their KOL programs through Within3. 12
  • 13. The leader in healthcare professional digital collaboration solutions Peter Gannon SVP, Business Partnerships 201-207-1952 pgannon@within3.com
  • 14. Clients use Within3 solutions across the drug lifecycle 14 Clinical Pre-Launch / Market Shaping Launch / Commercial End of Patent Advisory Board / Steering Committee / Focus Group Clinical Trial Speakers Bureau Custom HCP/KOL Engagement Solutions Third Party Sponsorship
  • 15. Sponsors site tremendous value from Hepatitis Circle. • Market Insight above and beyond what is available from traditional market research approaches • Market Visibility in multiple digital channels • Leverage within other KOL Programs such as advisory boards and steering committees • Robust quarterly reports that directly Inform Ongoing Strategy 15